Back to News
Market Impact: 0.28
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Johnson & Johnson CFO Joe Wolk said the company sees a path to growth above its previously stated 5%-7% long-term range. The outlook is supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility, signaling potential upside to the company’s existing long-term growth framework.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
JNJ0.55
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Ryanair CEO warns fares could rise by up to 20% in 2027 as fuel bill jumps by $2.2 billion
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist